


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims


1 1. (Previously presented) A method of modulating an endothelial gene differentiation-1
2 ("Edg-1") receptor mediated for vasoconstriction, comprising contacting a cell
3 expressing the Edg-1 receptor with an amount of a non-phospholipid modulator of the
4 Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated for vasoconstriction,
5 wherein said modulator is a compound of Formula (Ia):



6 (Ia)
7 or a pharmaceutically acceptable solvate or hydrate thereof, wherein
8 n is a member selected from the integers 0 to 5;
9 R¹ is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl,
10 acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted
11 alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy,
12 alkoxy carbonyl, substituted alkoxy carbonyl, alkylarylamino, substituted
13 alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted
14 aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino,
15 arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl,
16 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
17 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy,
18 heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;
19 each R², R³ and R⁵ is a member independently selected from the group consisting of
20 hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted

21 acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio,
22 alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl,
23 alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted
24 arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl,
25 arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy,
26 carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl,
27 cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted
28 dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted
29 heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and
30 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
31 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
32 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
33 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
34 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
35 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
36 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
37 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
38 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted
39 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
40 heteroalkyl, hydroxyl, nitro and thio.

1 2. (Previously presented) A method of modulating an Edg-1 receptor mediated for
2 vasoconstriction in a subject, comprising administering to the subject a therapeutically
3 effective amount of a non-phospholipid modulator of the Edg-1 receptor, wherein said
4 modulator is a compound of Formula (Ia):



5 (Ia)

6 or a pharmaceutically acceptable solvate or hydrate thereof, wherein:

7 n is a member selected from the integers 0 to 5;

8 R¹ is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl,
9 acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted
10 alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy,
11 alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted
12 alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted
13 aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino,
14 arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl,
15 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
16 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy,
17 heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

18 each R², R³ and R⁵ is a member independently selected from the group consisting of
19 hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted
20 acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio,
21 alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl,
22 alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted
23 arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl,
24 arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy,
25 carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl,
26 cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted
27 dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted
28 heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

29 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
30 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
31 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
32 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
33 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
34 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
35 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
36 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
37 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted
38 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
39 heteroalkyl, hydroxyl, nitro and thio.

1 **3.** (Canceled)

1 **4.** (Canceled)

1 **5.** (Canceled)

1 **6.** (Canceled)

1 **7.** (Canceled)

1 **8.** (Canceled)

1 **9.** (Canceled)

1 **10.** (Canceled)

1 **11.** (Canceled)

1 **12.** (Canceled)

1 **13.** (Canceled)

1 **14.** (Canceled)

1 **15.** (Canceled)

1 **16.** (Canceled)

1 **17.** (Canceled)

1 **18.** (Canceled)

1 **19.** (Canceled)

1 **20.** (Canceled)

1 **21.** (Canceled)

1 **22.** (Canceled)

1 **23.** (Canceled)

1 **24.** (Canceled)

1 **25.** (Canceled)

1 **26.** (Canceled)

1 **27.** (Canceled)

1 **28.** (Canceled)

1 **29.** (Canceled)


1 **30.** (Canceled)

1 **31.** (Canceled)

1 32. (Canceled)

1 33. (Canceled)

1 34. (Previously presented) A method for treating vasoconstriction in cerebral arteries in a
2 subject in need of such treatment, said method comprising administering to said subject a
3 therapeutically effective amount of a compound of Formula (Ia), wherein said compound
4 of Formula (Ia) is:



5 (Ia)

6 or a pharmaceutically acceptable solvate or hydrate thereof, wherein


7 n is a member selected from the integers 0 to 5;

8 R¹ is a member selected from the group consisting of hydrogen, alkyl, substituted
9 alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino,
10 substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted
11 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
12 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino,
13 aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted
14 arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl,
15 substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl,
16 substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino,
17 heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl,
18 heteroalkyl, and substituted heteroalkyl;

19 each R², R³ and R⁵ is a member independently selected from the group consisting of
20 hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino,
21 substituted acylamino, alkylamino, substituted alkylamino, alkylthio,


22 substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted
23 alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy,
24 substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted
25 arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted
26 arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl,
27 substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
28 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted
29 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
30 heteroalkyl, hydroxyl, nitro and thio; and
31 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
32 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
33 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
34 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
35 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
36 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
37 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
38 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
39 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted
40 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
41 heteroalkyl, hydroxyl, nitro and thio.

1 35. (Previously presented) A method for treating vasoconstriction in a subject in need of such
2 treatment, said method comprising administering to said subject a therapeutically
3 effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia)
4 is:



5 (Ia)
6 or a pharmaceutically acceptable solvate or hydrate thereof, wherein
7 n is a member selected from the integers 0 to 5;
8 R¹ is a member selected from the group consisting of hydrogen, alkyl, substituted
9 alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino,
10 substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted
11 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
12 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
13 substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted
14 arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl,
15 substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl,
16 substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino,
17 heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl,
18 heteroalkyl, and substituted heteroalkyl;
19 each R², R³ and R⁵ is a member independently selected from the group consisting of
20 hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino,
21 substituted acylamino, alkylamino, substituted alkylamino, alkylthio,
22 substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted
23 alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy,
24 substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted
25 arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted
26 arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl,
27 substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
28 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted

1 36. (Previously presented) A method for treating in a subject in need of such treatment, said
2 method comprising administering to said subject a therapeutically effective amount of a
3 compound of Formula (Ia), wherein said compound of Formula (Ia) is:




(Ia)


5 or a pharmaceutically acceptable solvate or hydrate thereof, wherein
6 n is a member selected from the integers 0 to 5;
7 R¹ is a member selected from the group consisting of hydrogen, alkyl, substituted
8 alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino,
9 substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted

10 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
11 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino,
12 aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted
13 arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl,
14 substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl,
15 substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino,
16 heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl,
17 heteroalkyl, and substituted heteroalkyl;
18 each R^2 , R^3 and R^5 is a member independently selected from the group consisting of
19 hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino,
20 substituted acylamino, alkylamino, substituted alkylamino, alkylthio,
21 substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted
22 alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy,
23 substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted
24 arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted
25 arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl,
26 substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
27 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted
28 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
29 heteroalkyl, hydroxyl, nitro and thio;
30 each R^4 is a member independently selected from the group consisting of hydrogen, halo,
31 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
32 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
33 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
34 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
35 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted
36 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano,
37 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
38 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted

39 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
40 heteroalkyl, hydroxyl, nitro and thio;
41 and one or more drugs useful in treating vasoconstriction.

1 37. (Previously presented) The method of Claim 1 or 2, wherein the modulator is a
2 compound of a formula that is selected from:





1 38. (Canceled)

1 39. (Canceled)

1 40. (Canceled)

1 41. (Canceled)

1 42. (Canceled)

1 43. (Canceled)

1 44. (Canceled)

1 **45.** (Canceled)

1 **46.** (Canceled)


1 **47.** (Canceled)

1 **48.** (Canceled)

1 **49.** (Canceled)

1 **50.** (Canceled)

1 **51.** (Previously presented) A method of treating vasoconstriction in a patient comprising:
2 administering to the patient a therapeutically effective amount of a modulator of an Edg-1
3 receptor wherein the modulator is a compound of Formula (Ib) is:




(Ib)

5 or a pharmaceutically acceptable solvate or hydrate thereof, wherein
6 n is a member selected from the integers 0 to 5;
7 R¹¹ is an aryl group;
8 each R² and R⁴ is a member independently selected from the group consisting of
9 hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino,
10 substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted
11 alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl,
12 alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted

1 52. (Previously presented) The method of claim 51, wherein said aryl group in R¹¹ is a
2 heteroaryl group.

1 53. (Previously presented) The method of claim 52, wherein said compound has the formula:



1 **54.** (Previously presented) The method of claim **53**, wherein R² is a substituted alkyl group.


1 **55.** (Previously presented) The method of claim **54**, wherein R² is said substituted alkyl
2 group is -CF₃.

1 **56.** (Previously presented) The method of claim **55**, wherein n is 1.

1 **57.** (Previously presented) The method of claim **56**, wherein R⁴ is a halo group.

1 **58.** (Previously presented) The method of claim **57**, wherein said halo group is chlorine.

2 **59.** (Previously presented) A method of treating vasoconstriction in a patient comprising:
3 administering to the patient a therapeutically effective amount of a modulator of an Edg-1
4 receptor wherein the modulator is a compound of Formula (Ic):



5 (Ic)

1 n is a member selected from the integers 0 to 5;
2 each R⁴ is a member independently selected from the group consisting of hydrogen, halo,
3 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino,
4 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy,
5 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino,
6 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl,
7 substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino,
8 arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl,
9 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
10 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy,
11 heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl,
12 nitro and thio.

1 60. (Previously presented) The method of claim 59, wherein n is 1.

1 61. (Previously presented) The method of claim 60, wherein R⁴ is a halo group.

1 62. (Previously presented) The method of claim 61, wherein said halo group is chlorine.

1 63. (Canceled)

1 64. (Canceled)